Scholars Central

OtherPublished 21 Jul 2016

An overview of satavaptan: a selective V2 receptor antagonist

Authors: Jareer Farah, Suleiman Daifallah, Hammam Zmily, Jalal K Ghali

Clinical Practice

Volume 7 · Issue 4 · Pages 409

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Satavaptan is a new selective V2 receptor antagonist that shares the aquaretic effect of the other arginine vasopressin antagonists. Its usefulness has been demonstrated in the correction of hyponatremia as well as in fluid removal in patients with cirrhosis. In addition, animal studies have suggested promising effects in the treatment of several other conditions, such as polycystic kidney disease, renal cell carcinoma, glaucoma, diabetic nephropathy and urinary tract infections. This article reviews the various animal and human studies that have outlined its potential clinical role and provided direction for further research with this drug.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Jareer Farah”
  • BylineArticles whose byline prints “Suleiman Daifallah”
  • BylineArticles whose byline prints “Hammam Zmily”
  • BylineArticles whose byline prints “Jalal K Ghali”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels